Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

Yeo, Anne-Emmanuella; Hendrix, Aurore; Confente, Caterina; Christian, Nicolas; Mansvelt, B.; Pairet, Géraldine; Seront, Emmanuel

doi:10.3389/fonc.2021.764758

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in another case study, a 66-year-old man with PCLM treated with radiofrequency ablation to the liver had no LM recurrence for 42 months [93]. Additionally, Yeo et al showed the potential for microwave needle ablation and SBRT to target LM [94]. While these case studies demonstrate promise, they need validation in prospective randomized trials.…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies

Shiner,

Sperandio,

Naimi

et al. 2024

JCM

View full text Add to dashboard Cite

Prostate cancer liver metastasis (PCLM), seen in upwards of 25% of metastatic castration-resistant PC (mCRPC) patients, is the most lethal site of mCRPC with a median overall survival of 10–14 months. Despite its ominous prognosis and anticipated rise in incidence due to longer survival with contemporary therapy, PCLM is understudied. This review aims to summarize the existing literature regarding the risk factors associated with the development of PCLM, and to identify areas warranting further research. A literature search was conducted through Ovid MEDLINE from 2000 to March 2023. Relevant subject headings and text words were used to capture the following concepts: “Prostatic Neoplasms”, “Liver Neoplasms”, and “Neoplasm Metastasis”. Citation searching identified additional manuscripts. Forty-one studies were retained for detailed analysis. The clinical risk factors for visceral/liver metastasis included <70 years, ≥T3 tumor, N1 nodal stage, de novo metastasis, PSA >20 ng/mL, and a Gleason score >8. Additional risk factors comprised elevated serum AST, LDH or ALP, decreased Hb, genetic markers like RB1 and PTEN loss, PIK3CB and MYC amplification, as well as numerous PC treatments either acting directly or indirectly through inducing liver injury. Further research regarding predictive factors, early detection strategies, and targeted therapies for PCLM are critical for improving patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies

Shiner,

Sperandio,

Naimi

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Successful radiofrequency ablation of liver metastases from prostate cancer

et al. 2022

View full text Add to dashboard Cite

Introduction: Patients with liver metastases from prostate cancer show poor prognosis. We performed metastases-directed therapy using radiofrequency ablation of liver metastases in an attempt to improve the prognosis in a patient with metastatic prostate cancer. Case presentation: We present the case of a 66-year-old man who was treated for metastatic castration-resistant prostate cancer. Evaluation showed isolated liver metastases together with elevated serum prostate-specific antigen levels. We performed metastases-directed therapy using radiofrequency ablation of the liver tumor. The patient showed no recurrent liver metastases for 42 months and survived for 66 months after diagnosis of metastatic prostate cancer. Conclusion: To our knowledge, this is the first report that describes radiofrequency ablation of liver metastases from prostate cancer. This procedure may be a useful therapeutic option for metastases-directed therapy in patients with liver metastases from prostate cancer.

show abstract

Cabazitaxel/docetaxel

2022

Reactions Weekly

View full text Add to dashboard Cite

Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

Cited by 3 publications

References 20 publications

Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies

Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies

Successful radiofrequency ablation of liver metastases from prostate cancer

Cabazitaxel/docetaxel

Contact Info

Product

Resources

About